Tscan Therapeutics Inc (TCRX)
TScan Therapeutics, Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker TCRX. The company focuses on developing T cell receptor-engineered T cell, or TCR-T, therapies for patients with cancer. Its lead candidate, TSC-101, is being evaluated in a Phase I clinical trial for patients with acute myeloid leukemia, myelodysplastic syndrome, and acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation. TSC-101 is also intended to help eliminate residual disease and support donor chimerism. TScan is also advancing TSC-102-A01 and TSC-102-A03, as well as a series of programs including TSC-200 through TSC-204 for solid tumor indications. In addition, the company has a research collaboration and license agreement with Amgen focused on identifying antigens recognized by T cells in Crohn’s disease. TScan Therapeutics was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TCRX
|
$0.46
|
31.9% Upside
|
Undervalued
|
$2.67
|
661.9% Upside
|
Bargain
|
Weak
|
0.0%
|
November 11, 2026
|
0.3x
|
3.1x
|
24.048 M
|
12.842 M
|
79.3%
|
85.3%
|
-6.2
|
100.6%
|
